Clinical Trials
14 trialsNCT05804669 2026-06-04
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
Crinetics Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT07296484 2026-05-12
CAPTAIN-T2D
Sparrow Pharmaceuticals
Phase 2 Recruiting
NCT05368090 2026-05-08
Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism
Haukeland University Hospital
Phase NA Recruiting
NCT03604198 2026-04-21
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Corcept Therapeutics
Phase 2 Active not recruiting
NCT07361874 2026-03-27
IMPACT-MACS
University of Texas Southwestern Medical Center
Phase NA Recruiting
NCT07412782 2026-02-17
REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)
Meyer Children's Hospital IRCCS
Phase NA Recruiting
NCT07104812 2026-02-11
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Mayo Clinic
Phase 2 Recruiting
NCT07247162 2025-12-10
LINC CARE
RECORDATI GROUP
Phase 4 Not yet recruiting
NCT06246357 2025-12-09
Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05307328 2025-10-08
RESCUE
Sparrow Pharmaceuticals
Phase 2 Completed
NCT06106295 2025-09-22
Metyrapone for Mild Autonomous Cortisol Secretion (MACS)
Mayo Clinic
Phase 2 Active not recruiting
NCT04308590 2025-09-04
GRADIENT
Corcept Therapeutics
Phase 3 Completed
NCT07138274 2025-08-22
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
Mayo Clinic
Phase 2 Not yet recruiting
NCT03697109 2025-07-16
GRACE
Corcept Therapeutics
Phase 3 Completed